Maravai Lifesciences Holdings (MRVI) Net Income towards Common Stockholders (2020 - 2026)

Maravai Lifesciences Holdings' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$6.4 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 87.93% year-over-year to -$6.4 million; the TTM figure through Mar 2026 stood at -$184.3 million (up 36.41% YoY), while the FY2025 annual figure was -$230.8 million, up 11.12% from the prior year.
• Net Income towards Common Stockholders was -$6.4 million for Q1 2026 at Maravai Lifesciences Holdings, up from -$63.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $156.7 million in Q2 2022 to a low of -$172.5 million in Q3 2024.
• Historically, Net Income towards Common Stockholders has averaged -$8.5 million across 5 years, with a median of -$18.4 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders soared 94.61% in 2022, then slumped 1582.49% in 2024.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $87.4 million in 2022, then sank by 225.8% to -$110.0 million in 2023, then surged by 58.11% to -$46.1 million in 2024, then slumped by 36.79% to -$63.0 million in 2025, then surged by 89.88% to -$6.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$6.4 million (Q1 2026), -$63.0 million (Q4 2025), and -$45.1 million (Q3 2025), per Business Quant data.